Status:
COMPLETED
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Breast Cancer
Eligibility:
FEMALE
33-96 years
Phase:
PHASE3
Brief Summary
Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females who recently underwent primary surgery for breast cancer. Patients will be randomized to letrozole (2.5 mg p...
Eligibility Criteria
Inclusion
- Recent primary surgery for breast cancer
- Early stage breast cancer
- Postmenopausal
- Hormone receptor positive
- Positive lymph node involvement
Exclusion
- Metastatic disease
- Presence of contralateral breast cancer including DCIS
- Progression
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
4172 Patients enrolled
Trial Details
Trial ID
NCT00248170
Start Date
December 1 2005
End Date
September 1 2014
Last Update
April 19 2016
Active Locations (259)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Hematology and Oncology Associates
Birmingham, Alabama, United States, 35205
2
Comprehensive Cancer Institute
Huntsville, Alabama, United States, 35801
3
Northern Arizona Hematology/Oncology Associates, P.C.
Flagstaff, Arizona, United States, 86001
4
Oncology & Hematology Associates, PC
New London, Connecticut, United States, 06320